DDInter1590 DDInter1676
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Rifampicin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifampicin {u} (Compound) treats {v} (Disease) leprosy
Rifampicin {u} (Compound) binds {v} (Gene) ABCC2
Rifampicin {u} (Compound) is included by {v} (Pharmacologic Class) Rifamycins
Rifampicin {u} (Compound) downregulates {v} (Gene) TIMP1
Rifampicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxepin
Rifampicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Rifampicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aluminum hydroxide
Rifampicin {u} may lead to a major life threatening interaction when taken with {v} Elagolix
Rifampicin (Compound) resembles Rifabutin (Compound)
Rifampicin (Compound) treats leprosy (Disease)
Rifampicin (Compound) binds ABCC2 (Gene)
Rifampicin (Compound) is included by Rifamycins (Pharmacologic Class)
Rifampicin (Compound) downregulates TIMP1 (Gene)
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Doxepin
Rifampicin may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Dapsone
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide
Rifampicin may lead to a major life threatening interaction when taken with Elagolix